lerodalcibep (LIB003) / LIB Therap 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
11 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
lerodalcibep (LIB003) / LIB Therap
2019-003611-62: Randomized, Open-Label, Phase 3 Study in which patients will receive LIB003 and Evolocumab to Evaluate the Efficacy and Safety in Homozygous Familial Hypercholesterolemia Patients on Stable Lipid-Lowering Therapy.

Not yet recruiting
3
70
Europe
LIB003, Solution for injection, Solution for injection in cartridge, Repatha (evolocumab)
LIB Therapeutics, LLC, LIB Therapeutics, LLC
Homozygous Familial Hypercholesterolemia, Homozygous familial hypercholesterolemia makes it harder for your body to remove LDL "bad" cholesterol from your blood. It is a disease you're born with., Diseases [C] - Nutritional and Metabolic Diseases [C18]
 
 
NCT04034485 / 2019-003611-62: Phase 3 Study to Evaluate the Efficacy and Safety of LIB003 With Evolocumab in HoFH

Completed
3
65
Europe, US, RoW
lerodalcibep, LIB003, evolocumab, Repatha
LIB Therapeutics LLC, LIB Therapeutics, LLC
Homozygous Familial Hypercholesterolemia
09/22
01/23
LIBerate-H2H, NCT04790513: Trial to Evaluate Efficacy and Safety of LIB003, Evolocumab and Alirocumab in High-risk CVD Patients

Completed
3
204
US
lerodalcibep, LIB003, evolocumab, Repatha, alirocumab, Praluent
LIB Therapeutics LLC
Hypercholesterolemia, Cardiovascular Diseases
09/22
12/22
LIBerate-FH, NCT04797104 / 2020-004390-44: Study to Assess the Efficacy and Safety of LIB003 in HeFH Patients on Oral Lipid Therapy Needing Further LDL-C Reduction

Completed
3
478
Europe, US, RoW
lerodalcibep, LIB003
LIB Therapeutics LLC, Medpace, Inc.
Heterozygous Familial Hypercholesterolemia
07/23
12/23
LIBerate-CVD, NCT04797247 / 2020-004392-40: Study of Efficacy and Safety of LIB003 in Patient With CVD on Statins Requiring Additional LDL-C Reduction

Active, not recruiting
3
900
US
lerodalcibep, LIB003
LIB Therapeutics LLC, Medpace, Inc.
Cardiovascular Diseases, Hyper-LDL-cholesterolemia
11/23
02/24
LIBerate-HR, NCT04806893 / 2020-004393-22: Study of Long-Term Efficacy and Safety of LIB003 in CVD or High Risk for CVD Patients Needing Further LDL-C Reduction

Active, not recruiting
3
900
US, RoW
lerodalcibep, LIB003, Placebo
LIB Therapeutics LLC, Medpace, Inc.
Cardiovascular Risk Factor, Cardiovascular Diseases, Cardiovascular Stroke, Hypercholesterolemia
11/23
02/24
LIBerate-VI, NCT05004675 / 2021-002871-20: Trial to Evaluate Efficacy and Safety of LIB003 and Inclisiran in High-risk CVD Patients

Completed
3
166
Europe
lerodalcibep, LIB003, Inclisiran, Leqvio
LIB Therapeutics LLC, Medpace, Inc.
Hypercholesterolemia, Atherosclerotic Ischemic Disease
05/24
10/24
LIBerate-OLE, NCT04798430 / 2020-004394-49: Long-term Efficacy and Safety of OLE LIB003 in HoFH, HeFH, and High-risk CVD Patients Requiring Further LDL-C Reduction

Enrolling by invitation
3
2000
Europe, US, RoW
lerodalcibep, LIB003
LIB Therapeutics LLC, Medpace, Inc.
Cardiovascular Disease With Mention of Arteriosclerosis, Elevated Cholesterol, Familial Hypercholesterolemia
07/25
12/25
NCT06568471: A Study on Efficacy and Safety of HST101 in Chinese Patients with Hypercholesterolemia

Recruiting
3
210
RoW
Lerodalcibep, HST101, LIB003, matching placebo
Hasten Biopharmaceutical Co., Ltd.
Hypercholesterolemia, Dyslipidemias, Primary Hypercholesterolemia, Heterozygous Familial Hypercholesterolemia, Hyperlipidemia; Mixed, Metabolic Disease, ASCVD
02/26
05/26
ChiCTR2400089193: To evaluate the efficacy and safety of HST101 (Ledaceibup) in Chinese patients with hypercholesterolemia

Not yet recruiting
3
210
 
subcutaneous injection HST101 ; subcutaneous injection placebo
Peking University First Hospital; Peking University First Hospital, Hasten Biopharmaceutical Co., Ltd
Hypercholesterolemia
 
 
NCT06504043: A Study on Evaluating the Safety of HST101 in Healthy Chinese Participants

Enrolling by invitation
1
30
RoW
HST101
Hasten Biopharmaceutical Co., Ltd., Medpace, Inc., Wuxi Apptec Co.,Ltd.
Hypercholesterolemia, Hyperlipidemias, Dyslipidemias, Lipid Metabolism Disorders, Metabolic Diseases
01/25
03/25

Download Options